Learn more about whether Immunocore Holdings plc or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Dyadic Announces Third Quarter 2025 Financial Results And Highlights Strategic Progress. <li /> Completed strategic pivot from R&D focus to commercial focus <li /> Rebranded as Dyadic Applied BioSolu ...

Amgen announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell ...

The cosmetics and personal care segment remains the dominant end-use area, capturing 50.6% of market share in 2025.

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Exclusive data analysis carried out by FutureBridge on behalf of Food Manufacture has identified the top 100 hottest food and ...

CBSE Class 12 Biology Exam Pattern and Marking Scheme 2025-26: The Central Board of Secondary Education (CBSE) will conduct the Class 12 Biology exam in 2026 based on a specific, structured pattern ...

Teens at a Georgia high school may have come up with a better way to detect and treat Lyme disease. They took their idea to ...

Plasmid Purification Market to reach USD 6.6 Bn by 2035 at 12.3% CAGR, Driven by rising gene therapy demand, mRNA vaccines, ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) ...